secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0001193125-25-140339
Event type: regulatory
Sentiment:  positive
Materiality: 0.95
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves UroGen Pharma's ZUSDURI (mitomycin) for recurrent LG-IR-NMIBC
--------------------------------------------------------------------------

- FDA approved ZUSDURI (mitomycin) for adults with recurrent low-grade intermediate-risk NMIBC on June 12, 2025.
- Phase 3 ENVISION trial: 78% achieved complete response at 3 months; 79% of those maintained at 12 months.
- Expected commercial availability in the U.S. on or around July 1, 2025.
- Common adverse reactions include increased creatinine, dysuria, hematuria; serious reactions in 12% of patients.
- Post-marketing commitment: ongoing ENVISION trial to further characterize clinical benefit; annual duration of response updates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312525140339/0001193125-25-140339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312525140339/d98388d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-140339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer